CASE REPORT

A surgical case of ciliated muconodular papillary tumor

Xiaojun Yao¹,², Yanrong Gong³, Jian Zhou¹,³, Mengyuan Lyu³, Hongwei Zhang², Haining Zhou⁴, Qichi Luo⁵ & Lunxu Liu¹,⁶

¹ Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China
² Department of Thoracic Surgery, Meishan Cancer Hospital, Meishan, China
³ West China School of Medicine, Sichuan University, Chengdu, China
⁴ Department of Thoracic Surgery, Suining Central Hospital, Suining, China
⁵ Department of Pathology, Suining Central Hospital, Suining, China
⁶ Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, China

Keywords
Ciliated muconodular papillary tumor; recurrence; surgery.

Correspondence
Lunxu Liu, Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan 610041, China.
Tel: +86 28 8542 2494
Fax: +86 28 8542 2494
E-mail: lunxu_liu@aliyun.com

Received: 6 December 2018;
Accepted: 13 January 2019.
doi: 10.1111/1759-7714.12997

Thoracic Cancer 10 (2019) 1019–1022

Abstract
Ciliated muconodular papillary tumor (CMPT) is a rare type of pulmonary tumor with mucoid features. Only a few cases confirmed by surgery have been reported worldwide. We report a case of CMPT following sublobectomy, with no recurrence detected in 10 months of follow-up. The accumulation of similar cases is essential for pathologists and surgeons to improve their understanding of such tumors.

Introduction
Ciliated muconodular papillary tumor (CMPT) is a rare type of pulmonary tumor with mucoid features. Only a few cases confirmed by surgery have been reported worldwide,¹⁻³ with more cases reported in East Asia than in Europe or America.⁴ Because of the lack of typical clinical manifestations and image changes, it is difficult to differentiate benignity from malignancy and CMPT can easily be misdiagnosed as adenocarcinoma.⁵ Herein we report a case of CMPT following sublobectomy, with no recurrence found during 10 months of follow-up.

Case report
A 67-year-old woman was initially detected with a nodule on the left upper lobe without any symptoms. No significant image changes were identified within three months of follow-up. She was admitted to our hospital for further evaluation on 2 January 2018. Contrast-enhanced computed tomography (CT) indicated an irregular solid nodule with a maximum diameter of 1.2 cm in the lingual segment of the left upper pulmonary lobe (Fig 1). No enlarged hilar and mediastinal lymph nodes were identified. The serum levels of tumor markers, including carcinoembryonic antigen, neuron-specific enolase, cytokeratin-19 fragment, squamous cell carcinoma antigen, and pro-gastrin releasing peptide were normal. No abnormalities were found in head magnetic resonance imaging, abdominal CT, or bone scan. We recommended positron emission tomography-CT (PET-CT) examination to the patient, but she refused because of the high cost. A multidisciplinary team performed comprehensive preoperative evaluation and highly suspected that the nodule was peripheral lung cancer. We performed thoracoscopic left pulmonary-lingual segmentectomy. Grossly, the tumor was solid, grey-white, with a
soft texture and clear boundaries. An intraoperative frozen section indicated a benign lesion therefore we did not perform hilar and mediastinal lymph node dissection.

Postoperative pathological examination showed that the tumor cell consisted of proliferated epithelium with adenoid and papillary structures, including ciliated columnar cells, mucous cells, and basal cells. Ciliated columnar cells were coated on the surface of adenoid or papillary structures. Basal cells were located in the outer layer. The alveolar cavity around the lesion was filled with mucus. Tumor cells showed no atypia, mitosis or necrosis (Fig 2). The immunohistochemical profile of the ciliated columnar cells and mucous cells showed that CK 7 was positive; TTF-1 was weakly positive; and CK20, CD56, NCAM1, MUC5AC, Napsin A and P63 were negative.

CMPT showed a low Ki-67 proliferating index (Fig 3). Finally, the case was pathologically diagnosed as CMPT.

The patient recovered unevenly after surgery, and no recurrence was found within 10 months of follow-up.

Discussion

In 2002, Ishikawa et al. first reported a case of CMPT, which was characterized by tripartite cellular components with a papillary-predominant structure including ciliated columnar cells, mucinous cells, and basal cells. This tumor is extremely rare, and has not been included in the World Health Organization classification of lung tumors.

CMPT does not present any symptoms and is usually detected during routine physical examination. It can also be accompanied by some common and non-specific respiratory symptoms. CT findings of CMPT patients are mostly atypical solitary peripulmonary nodules. For pulmonary nodules with a diameter of the solid component of > 8 mm, PET-CT is helpful in differentiating benignity from malignancy. However, high cost restricts the wide clinical use of PET-CT. Furthermore, it is also challenging to perform a non-operative biopsy, including bronchoscopy and percutaneous puncture. Therefore, CMPT is commonly misdiagnosed as lung cancer by surgeons and radiologists before surgery. A multidisciplinary team, including thoracic surgeons, radiologists, oncologists, and pulmonologists, should be organized to comprehensively identify the optimal diagnostic and therapeutic strategy.

The key to a diagnosis of CMPT is to identify: (i) ciliated columnar cells and basal cells; (b) papillary tumors accompanied with mucus production; and (c) tumor cells without atypia, nuclear division, or necrosis. Usually, the immunohistochemical profile of the ciliated columnar cells and mucous cells shows positive CK7 and negative CK20. Some studies have reported focally weak TTF-1 expression, while others have indicated no TTF-1 expression in CMPT. In this patient, the basal cells expressed P63 and P40; the ciliated columnar cells partly expressed MUC5AC, while mucous cells did not; and they all had a low Ki-67 proliferating index in general.

No consensus has been reached on the benignity or malignancy of CMPT. Some scholars believe that CMPT may be a precancerous lesion or a low-grade malignant tumor of mucinous adenocarcinoma, because of the histological and molecular biological characteristics related to malignancy. However, most research considers CMPT as a benign lesion, given that the pulmonary tumors with cilia are commonly benign.

Local resection is the mainstream treatment for CMPT patients. However, because of its clinical rarity and the lack of uniform diagnostic criteria, pathologists continue to try and identify predictive factors. If CMPT is misdiagnosed...
as lung adenocarcinoma in intraoperative frozen sections or malignancy cannot be excluded, lobectomy and mediastinal lymph node dissection are considered.\textsuperscript{1,5,8} In this case, a malignant tumor was highly suspected before surgery. Lung segmental resection can achieve radical tumor resection and avoid unnecessary surgery.

In recent years, segmental resection has been widely performed for early-stage lung cancer. When a pulmonary nodule is highly suspected as malignant before surgery and meets segmental resection indications, segmental resection can be considered to achieve complete resection. The decision over whether to dissect mediastinal lymph nodes is made according to intraoperative frozen sections.

In summary, CMPT is a rare type of lung cancer. It usually presents in CT examination as an accidental lung nodule. According to the current evidence, CMPT tends to be benign, but more case data is required to determine long-term biological behavior. The accumulation of similar cases is essential for pathologists and surgeons to improve their understanding of such tumors.

Acknowledgment

This work was supported by the Key Science and Technology Program of Sichuan Province, China (2016FZ0118).

Disclosure

Authors report no conflict of interest.

References

1. Kamata T, Yoshida A, Kosuge T, Watanabe SI, Asamura H, Tsuta K. Ciliated Muconodular papillary tumors of the lung: a clinicopathologic analysis of 10 cases. Am J Surg Pathol 2015; 39 (6): 753–60.
2. Miyai K, Takeo H, Nakayama T et al. Invasive form of ciliated muconodular papillary tumor of the lung: A case report and review of the literature. Pathol Int 2018; 68 (9): 530–5.
3. Zheng Q, Luo R, Jin Y et al. So-called "non-classic" ciliated Muconodular papillary tumors: A comprehensive comparison of the Clinicopathological and molecular features with classic ciliated Muconodular papillary tumors. Hum Pathol 2018; 82: 193–201.
4. Liu L, Aesif SW, Kipp BR et al. Ciliated muconodular papillary tumors of the lung can occur in Western patients and show mutations in BRAF and AKT1. Am J Surg Pathol 2016; 40: 1631–6.
5. Chu HH, Park SY, Cha EJ. Ciliated muconodular papillary tumor of the lung: The risk of false-positive diagnosis in frozen section. Human Pathol 2017; 7: 8–10.
6. Ishikawa Y. Ciliated muconodular papillary tumor of the peripheral lung: Benign or malignant? Pathol Clin Med (Byori-To-Rinsho) 2002; 20: 964–5.
7. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer. 2002; 20: 964–5. (Version 1. 2019). [Cited 19 October].
8. Chang JC, Montecalvo J, Borsu L et al. Bronchiolar adenoma: Expansion of the concept of ciliated Muconodular papillary tumors with proposal for revised terminology based on morphologic, immunophenotypic, and genomic analysis of 25 cases. Am J Surg Pathol 2018; 42: 1010–26.
9 Kataoka T, Okudela K, Matsumura M et al. A molecular pathological study of four cases of ciliated muconodular papillary tumors of the lung. Pathol Int 2018; 68: 353–8.
10 Kon T, Baba Y, Fukai I, Watanabe G, Uchiyama T, Murata T. Ciliated muconodular papillary tumor of the lung: A report of five cases. Pathol Int 2016; 66: 633–9.
11 Sato S, Koike T, Homma K, Yokoyama A. Ciliated muconodular papillary tumour of the lung: A newly defined low-grade malignant tumour. Interact Cardiovasc Thorac Surg 2010; 11: 685–7.
12 Udo E, Furusato B, Sakai K et al. Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation. Diagn Pathol 2017; 12: 62.